BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 27123743)

  • 1. Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus.
    Van Der Meeren O; Peterson JT; Dionne M; Beasley R; Ebeling PR; Ferguson M; Nissen MD; Rheault P; Simpson RW; De Ridder M; Crasta PD; Miller JM; Trofa AF
    Hum Vaccin Immunother; 2016 Aug; 12(8):2197-2203. PubMed ID: 27123743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years.
    Gilbert CL; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
    Hum Vaccin; 2011 Dec; 7(12):1336-42. PubMed ID: 22185811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults.
    Jackson S; Lentino J; Kopp J; Murray L; Ellison W; Rhee M; Shockey G; Akella L; Erby K; Heyward WL; Janssen RS;
    Vaccine; 2018 Jan; 36(5):668-674. PubMed ID: 29289383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: An integrated analysis.
    Van Der Meeren O; Crasta P; Cheuvart B; De Ridder M
    Hum Vaccin Immunother; 2015; 11(7):1726-9. PubMed ID: 25996260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of HBV vaccine during stated shelf-life.
    Gloriani NG; Srinivasa K; Bock HL; Hoet B
    Southeast Asian J Trop Med Public Health; 2010 Jul; 41(4):876-82. PubMed ID: 21073062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal pre-dialysis and dialysis patients.
    Gilbert CL; Stek JE; Villa G; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
    Vaccine; 2014 Nov; 32(48):6521-6. PubMed ID: 25252192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60-70 years.
    Hyer RN; Janssen RS
    Vaccine; 2019 Sep; 37(39):5854-5861. PubMed ID: 31431412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effect of two different doses of recombinant hepatitis B vaccine on immunogenicity in healthy adults.
    Li J; Yao J; Shan H; Chen Y; Jiang ZG; Ren JJ; Xu KJ; Ruan B; Yang SG; Wang B; Xie TS; Li Q
    Hum Vaccin Immunother; 2015; 11(5):1108-13. PubMed ID: 25607773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus vaccination for older adults.
    Bennett RG; Powers DC; Remsburg RE; Scheve A; Clements ML
    J Am Geriatr Soc; 1996 Jun; 44(6):699-703. PubMed ID: 8642163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines.
    Wheeler CM; Bautista OM; Tomassini JE; Nelson M; Sattler CA; Barr E;
    Vaccine; 2008 Jan; 26(5):686-96. PubMed ID: 18164106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a Haemophilus influenzae B (Hib)-hepatitis B vaccine with a modified process hepatitis B component administered with concomitant pneumococcal conjugate vaccine to infants.
    Lee AW; Vesikari T; Gilbert CL; Klopfer SO; Schödel FP; Bhuyan PK
    Vaccine; 2011 Oct; 29(45):7942-8. PubMed ID: 21875633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of a new, low-cost recombinant hepatitis B vaccine derived from Hansenula polymorpha in adults.
    Kulkarni PS; Raut SK; Patki PS; Phadke MA; Jadhav SS; Kapre SV; Dhorje SP; Godse SR
    Vaccine; 2006 Apr; 24(17):3457-60. PubMed ID: 16530299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents.
    Schiff GM; Sherwood JR; Zeldis JB; Krause DS
    J Adolesc Health; 1995 Jan; 16(1):12-7. PubMed ID: 7742331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial.
    Rey D; Piroth L; Wendling MJ; Miailhes P; Michel ML; Dufour C; Haour G; Sogni P; Rohel A; Ajana F; Billaud E; Molina JM; Launay O; Carrat F;
    Lancet Infect Dis; 2015 Nov; 15(11):1283-91. PubMed ID: 26257021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients.
    el-Reshaid K; al-Mufti S; Johny KV; Sugathan TN
    Vaccine; 1994; 12(3):223-34. PubMed ID: 8165854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults.
    Hernández-Bernal F; Aguilar-Betancourt A; Aljovin V; Arias G; Valenzuela C; de Alejo KP; Hernández K; Oquendo O; Figueredo N; Figueroa N; Musacchio A; Véliz G; García E; Mollineda AD; Juvier AI; Trujillo J; Delahanty A; Ortega D; Cinza Z; González VL
    Hum Vaccin; 2011 Oct; 7(10):1026-36. PubMed ID: 21941089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study.
    Sapru A; Kulkarni PS; Bhave S; Bavdekar A; Naik SS; Pandit AN
    J Trop Pediatr; 2007 Oct; 53(5):303-7. PubMed ID: 17478542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical Trial.
    Vesikari T; Finn A; van Damme P; Leroux-Roels I; Leroux-Roels G; Segall N; Toma A; Vallieres G; Aronson R; Reich D; Arora S; Ruane PJ; Cone CL; Manns M; Cosgrove C; Faust SN; Ramasamy MN; Machluf N; Spaans JN; Yassin-Rajkumar B; Anderson D; Popovic V; Diaz-Mitoma F;
    JAMA Netw Open; 2021 Oct; 4(10):e2128652. PubMed ID: 34636914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.
    Janssen RS; Mangoo-Karim R; Pergola PE; Girndt M; Namini H; Rahman S; Bennett SR; Heyward WL; Martin JT
    Vaccine; 2013 Nov; 31(46):5306-13. PubMed ID: 23727422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of antigen dosage on the hepatitis B vaccine response in infants born to hepatitis B-uninfected and hepatitis B-infected mothers.
    Kang G; Ma F; Chen H; Yang Y; Guo S; Wang Z; Liang X; Li L; Cui F; Zhang L
    Vaccine; 2015 Aug; 33(33):4093-9. PubMed ID: 26144895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.